» Articles » PMID: 29520054

Patient-derived Xenograft Cryopreservation and Reanimation Outcomes Are Dependent on Cryoprotectant Type

Overview
Journal Lab Invest
Specialty Pathology
Date 2018 Mar 10
PMID 29520054
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Patient-derived xenografts (PDX) are being increasingly utilized in preclinical oncologic research. Maintaining large colonies of early generation tumor-bearing mice is impractical and cost-prohibitive. Optimal methods for efficient long-term cryopreservation and subsequent reanimation of PDX tumors are critical to any viable PDX program. We sought to compare the performance of "Standard" and "Specialized" cryoprotectant media on various cryopreservation and reanimation outcomes in PDX tumors. Standard (10% DMSO media) and Specialized (Cryostor®) media were compared between overall and matched PDX tumors. Primary outcome was reanimation engraftment efficiency (REE). Secondary outcomes included time to tumor formation (TTF), time to harvest (TTH), and potential loss of unique PDX lines. Overall 57 unique PDX tumors underwent 484 reanimation engraftment attempts after previous cryopreservation. There were 10 unique PDX tumors cryopreserved with Standard (71 attempts), 40 with Specialized (272 attempts), and 7 with both (141 attempts). Median frozen time of reanimated tumors was 29 weeks (max. 177). Tumor pathology, original primary PDX growth rates, frozen storage times, and number of implantations per PDX model were similar between cryoprotectant groups. Specialized media resulted in superior REE (overall: 82 vs. 39%, p < 0.0001; matched: 97 vs. 36%, p < 0.0001; >52 weeks cryostorage: 59 vs. 9%, p < 0.0001), shorter TTF (overall 24 vs. 54 days, p = 0.0051; matched 18 vs. 53 days, p = 0.0013) and shorter TTH (overall: 64 vs. 89 days, p = 0.009; matched: 47 vs. 88 days, p = 0.0005) compared to Standard. Specialized media demonstrated improved REE with extended duration cryostorage (p = 0.048) compared to Standard. Potential loss of unique PDX lines was lower with Specialized media (9 vs. 35%, p = 0.017). In conclusion, cryopreservation with a specialized cryoprotectant appears superior to traditional laboratory-based media and can be performed with reliable reanimation even after extended cryostorage.

Citing Articles

Establishment and Its Utility of a Patient-Derived Cell Xenografts (PDCX) Model with Cryopreserved Cancer Cells from Human Tumor.

Kim K, Lee J, Lee E, Jung D, Goh A, Choi M Cells. 2025; 14(5).

PMID: 40072054 PMC: 11898490. DOI: 10.3390/cells14050325.


Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics.

Bokhout L, Campeiro J, Dalm S Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40016527 DOI: 10.1007/s00259-025-07123-3.


Culture of cryopreserved first trimester placental tissues to study syncytial renewal.

Mansilla M, Wang Y, Nie G Sci Rep. 2025; 15(1):4873.

PMID: 39929934 PMC: 11810994. DOI: 10.1038/s41598-025-89022-z.


Gastrointestinal Cancer Patient Derived Organoids at the Frontier of Personalized Medicine and Drug Screening.

Yang Z, Yu J, Wong C Cells. 2024; 13(16.

PMID: 39195202 PMC: 11352269. DOI: 10.3390/cells13161312.


Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models.

Wang E, Xiang K, Zhang Y, Wang X J Natl Cancer Cent. 2024; 2(4):263-276.

PMID: 39036550 PMC: 11256726. DOI: 10.1016/j.jncc.2022.10.001.


References
1.
Alkema N, Tomar T, Duiker E, Meersma G, Klip H, van der Zee A . Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods. Sci Rep. 2015; 5:14495. PMC: 4594124. DOI: 10.1038/srep14495. View

2.
Mazur P . Freezing of living cells: mechanisms and implications. Am J Physiol. 1984; 247(3 Pt 1):C125-42. DOI: 10.1152/ajpcell.1984.247.3.C125. View

3.
Williams S, Anderson W, Santaguida M, Dylla S . Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Invest. 2013; 93(9):970-82. DOI: 10.1038/labinvest.2013.92. View

4.
Sosef M, Baust J, Sugimachi K, Fowler A, Tompkins R, Toner M . Cryopreservation of isolated primary rat hepatocytes: enhanced survival and long-term hepatospecific function. Ann Surg. 2004; 241(1):125-33. PMC: 1356855. DOI: 10.1097/01.sla.0000149303.48692.0f. View

5.
Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C . An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006; 12(15):4652-61. DOI: 10.1158/1078-0432.CCR-06-0113. View